An open, randomised, comparative, multicentre study of the immunogenicity and safety of ProQuad [MMR-varicella zoster virus vaccine] when administered by intramuscular (IM) route or subcutaneous (SC) route to healthy children aged 12 to 18 months.
Phase of Trial: Phase III
Latest Information Update: 17 Mar 2017
At a glance
- Drugs MMR-varicella zoster virus vaccine (Primary) ; MMR-varicella zoster virus vaccine (Primary)
- Indications Chickenpox; Measles; Mumps; Rubella
- Focus Pharmacodynamics
- Sponsors sanofi pasteur MSD
- 01 Jul 2008 Actual end date changed from 1 May 07 to 1 January 2008, reported by Clinicaltrals.gov.
- 27 Oct 2007 Status changed from in progress to completed.
- 01 Mar 2007 New trial record.